Skip to main content

RXRA KO cell line available to order. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Be the first to review this product! Submit a review

Images

Western blot - Human RXRA knockout HCT116 cell line (AB273708), expandable thumbnail
  • Immunocytochemistry/ Immunofluorescence - Human RXRA knockout HCT116 cell line (AB273708), expandable thumbnail
  • Sanger Sequencing - Human RXRA knockout HCT116 cell line (AB273708), expandable thumbnail
  • Western blot - Human RXRA knockout HCT116 cell line (AB273708), expandable thumbnail

Key facts

Cell type
HCT116
Species or organism
Human
Tissue
Colon
Form
Liquid
Knockout validation
Immunocytochemistry, Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1

Alternative names

FLJ00280, FLJ00318, FLJ16020, FLJ16733, MGC102720, NR2B1, Nuclear receptor subfamily 2 group B member 1, OTTHUMP00000022510, RXR alpha1, RXRA_HUMAN, Retinoic acid receptor RXR-alpha, Retinoid X nuclear receptor alpha, Retinoid X receptor alpha

Recommended products

RXRA KO cell line available to order. KO validated by Immunocytochemistry, Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.

Key facts

Cell type
HCT116
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1
Antibiotic resistance
Puromycin 1µg/mL
Disease
Carcinoma
Concentration
Loading...

Properties

Gene name
RXRA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Immunocytochemistry, Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
McCoY5a + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HCT116 cell line (ab273730). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Retinoid X Receptor alpha (RXRA) also referred to as NR2B1 is a nuclear receptor with a mass of approximately 55 kDa. RXRA functions as a transcription factor and plays a significant role in regulating gene expression by forming heterodimers with other nuclear receptors. RXRA is expressed in many tissues with notable levels in organs like the liver lungs and kidneys. Its ability to bind DNA sequences known as retinoic acid response elements allows RXRA to regulate diverse physiological processes.

Biological function summary

RXRA serves an important role in metabolic regulation especially in lipid metabolism and glucose homeostasis. It forms heterodimers with partners such as peroxisome proliferator-activated receptors (PPARs) enhancing its capacity to modulate various metabolic pathways. These heterodimers facilitate the transcription of genes that respond to nutritional changes. RXRA also influences immune responses and cell differentiation making it important for maintaining cellular health.

Pathways

RXRA operates within the retinoid signaling and lipid metabolism pathways. Through its interaction with PPARs particularly PPAR-γ and PPAR-α RXRA becomes an integral part of the signaling that controls fatty acid storage and glucose metabolism. These pathways influence cellular function and energy balance impacting the body's overall metabolic status.

Associated diseases and disorders

RXRA has associations with metabolic diseases such as diabetes and cardiovascular disorders. Dysregulation of RXRA expression or function can disrupt lipid and glucose metabolism leading to insulin resistance and metabolic syndrome. The RXRA-PPAR-γ interaction is essential in these conditions with the pair influencing adipogenesis and inflammatory responses. Understanding and targeting RXRA interactions can provide therapeutic prospects for these metabolic disorders.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com